FY2029 EPS Forecast for Viridian Therapeutics Cut by Analyst

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at Leerink Partnrs cut their FY2029 earnings estimates for Viridian Therapeutics in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now expects that the company will earn $2.85 per share for the year, down from their previous estimate of $3.00. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share.

Several other equities research analysts have also issued reports on the company. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. TD Cowen began coverage on Viridian Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating for the company. Royal Bank of Canada increased their price target on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. HC Wainwright restated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Price Performance

NASDAQ:VRDN traded down $1.12 during midday trading on Monday, hitting $14.41. The company had a trading volume of 1,219,704 shares, compared to its average volume of 1,179,288. The company has a market capitalization of $1.14 billion, a PE ratio of -3.34 and a beta of 1.32. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20. The stock's fifty day moving average price is $18.20 and its 200-day moving average price is $19.70.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.

Institutional Trading of Viridian Therapeutics

Institutional investors have recently modified their holdings of the company. R Squared Ltd bought a new position in Viridian Therapeutics during the 4th quarter valued at approximately $26,000. Foresite Capital Management VI LLC purchased a new position in shares of Viridian Therapeutics during the fourth quarter valued at approximately $38,000. AlphaQuest LLC raised its holdings in shares of Viridian Therapeutics by 119.0% during the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after acquiring an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after acquiring an additional 1,516 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Viridian Therapeutics in the third quarter worth $149,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.